Investigating NKAPL, a potential marker for platinum resistance, in high-grade serous ovarian cancer

被引：0
|
作者：
Schafer, Lea [1 ,2 ]
Silva, Romina [1 ,2 ]
Stewart, Gavin [1 ]
O'Toole, Sharon [3 ]
Perry, Antoinette [1 ,2 ]
机构：
[1] Univ Coll Dublin, Sch Biol & Environm Sci, Dublin, Ireland
[2] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Canc Biol & Therapeut Lab, Dublin, Ireland
[3] Trinity Coll Dublin, Obstet & Gynaecol Histopathol, Dublin, Ireland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EV019/#412
引用
收藏
页码：A92 / A93
页数：2
相关论文
共 50 条
  • [21] The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
    Yan, Shunfei
    Frank, Daniel
    Son, Jinbae
    Hannan, Katherine M.
    Hannan, Ross D.
    Chan, Keefe T.
    Pearson, Richard B.
    Sanij, Elaine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (01):
  • [22] WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
    Yu, Hai-Lan
    Ma, Xu-Dong
    Tong, Jin-Fei
    Li, Jian-Qiong
    Guan, Xiao-Jing
    Yang, Jian-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 6191 - 6201
  • [23] Epigenomic signatures of acquired platinum resistance in high grade serous ovarian cancer
    Fang, Fang
    Cardenas, Horacio
    Jiang, Guanglong
    Perkins, Susan M.
    Zhang, Chi
    Keer, Harold
    Liu, Yunlong
    Matei, Daniela
    Nephew, Kenneth
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Differentially expressed genes in platinum-resistant high-grade serous ovarian cancer
    Corey, Logan
    Alvero, Ayesha
    Tiwari, Nivedita
    You, Yuan
    Rattan, Ramandeep
    Kim, Seongho
    Mor, Gil
    Gogoi, Radhika
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S130 - S131
  • [25] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [26] Characterisation of Proteomic heterogeneity following platinum therapy in High-grade Serous Ovarian Cancer
    Wulandari, Ratri
    Nixon, Katherine
    Rama, Nona
    Curry, Ed
    Cunnea, Paula
    Fotopoulou, Christina
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 40 - 41
  • [27] Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction
    Kilim, Oz
    Olar, Alex
    Biricz, Andras
    Madaras, Lilla
    Pollner, Peter
    Szallasi, Zoltan
    Sztupinszki, Zsofia
    Csabai, Istvan
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [28] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
  • [29] Investigating the Clinical Utility of a Targeted ctDNA Panel for High-grade Serous Ovarian Cancer
    Kelly, Tanya
    Ward, Mark
    Lewis, Faye
    Henderson, Brian
    Hurley, Sinead
    Norris, Lucy
    Martin, Cara
    Kamran, Waseem
    Abu Saadeh, Feras
    O'Leary, John
    O'Toole, Sharon
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1182 - S1182
  • [30] Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer
    Ay, Seval
    Ozyukseler, Deniz Tataroglu
    Dulgar, Ozgecan
    Basak, Mustafa
    Yildirim, Mahmut Emre
    Gumus, Mahmut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (06): : 651 - 656
12345